Literature DB >> 31446847

TRIAGE-STROKE: Treatment strategy In Acute larGE vessel occlusion: Prioritize IV or endovascular treatment-A randomized trial.

Anne Behrndtz1, Søren P Johnsen2, Jan B Valentin2, Martin F Gude3, Rolf A Blauenfeldt1, Grethe Andersen1, Charles Blm Majoie4, Marc Fisher5, Claus Z Simonsen1.   

Abstract

RATIONALE: For patients with acute ischemic stroke and large vessel occlusions, intravenous thrombolysis and endovascular therapy are standard of care, but the effect of endovascular therapy is superior to intravenous thrombolysis. If a severe stroke with symptoms indicating large vessel occlusions occurs in the catchment area of a primary stroke center, there is equipoise regarding optimal transport strategy. AIM: For patients presenting with suspected large vessel occlusions (PASS ≥ 2) and a final diagnosis of acute ischemic stroke, we hypothesize that bypassing the primary stroke center will result in an improved 90-day functional outcome. SAMPLE SIZE: We aim to randomize 600 patients, 1:1.
DESIGN: A national investigator-driven, multi-center, randomized assessor-blinded clinical trial. The Prehospital Acute Stroke Severity Scale has been developed. It identifies most patients with large vessel occlusions in the pre-hospital setting. Patients without a contraindication for intravenous thrombolysis are randomized to either transport directly to a comprehensive stroke centers for intravenous thrombolysis and of endovascular therapy or to a primary stroke center for intravenous thrombolysis and subsequent transport to a comprehensive stroke centers for of endovascular therapy, if needed. OUTCOMES: The primary outcome will be the 90-day modified Rankin Scale score (mRS) for all patients with acute ischemic stroke. Secondary outcomes include 90-day mRS for all randomized patients, all patients with ischemic stroke but without large vessel occlusions, and patients with hemorrhagic stroke. The safety outcomes include severe dependency or death and time to intravenous thrombolysis for ischemic stroke patients. DISCUSSION: Study results will influence decision making regarding transport strategy for patients with suspected large vessel occlusions.

Entities:  

Keywords:  Acute ischemic stroke; drip-and-ship vs. mothership; endovascular therapy; prehospital triage

Year:  2019        PMID: 31446847     DOI: 10.1177/1747493019869830

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  5 in total

1.  Stroke Network of Wisconsin (SNOW) Scale Predicts Large Vessel Occlusion Stroke in the Prehospital Setting.

Authors:  Kessarin Panichpisal; Sarah Erpenbeck; Paul Vilar; Reji P Babygirija; Maharaj Singh; M Riccardo Colella; Richard A Rovin
Journal:  J Patient Cent Res Rev       Date:  2022-04-18

2.  CTA Protocols in a Telestroke Network Improve Efficiency for Both Spoke and Hub Hospitals.

Authors:  A T Yu; R W Regenhardt; C Whitney; L H Schwamm; A B Patel; C J Stapleton; A Viswanathan; J A Hirsch; M Lev; T M Leslie-Mazwi
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-04       Impact factor: 3.825

3.  Can Helicopters Solve the Transport Dilemma for Patients With Symptoms of Large-Vessel Occlusion Stroke in Intermediate Density Areas? A Simulation Model Based on Real Life Data.

Authors:  Anne Behrndtz; Richard Beare; Svitlana Iievlieva; Grethe Andersen; Jeppe Mainz; Martin Gude; Henry Ma; Velandai Srikanth; Claus Z Simonsen; Thanh Phan
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

Review 4.  Recanalization Therapy for Acute Ischemic Stroke with Large Vessel Occlusion: Where We Are and What Comes Next?

Authors:  Mohammad Shafie; Wengui Yu
Journal:  Transl Stroke Res       Date:  2021-01-06       Impact factor: 6.829

5.  Quality assurance data for regional drip-and-ship strategies- gearing up the transfer process.

Authors:  Erendira G Boss; Ferdinand O Bohmann; Björn Misselwitz; Manfred Kaps; Tobias Neumann-Haefelin; Waltraud Pfeilschifter; Natalia Kurka
Journal:  Neurol Res Pract       Date:  2021-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.